Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | NQO2 | P16083 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12053150 | 0.90 | NQO2 (0.46) | CYP19A1NQO2PDE4BPDE4D | |
| SCHEMBL729199 | 0.90 | PDE4B (0.51) | PDE4BPDE4D | |
| SCHEMBL730828 | 0.85 | NQO2 (0.49) | CYP19A1NQO2PDE4B | |
| SCHEMBL728526 | 0.84 | PDE4B (0.54) | CYP19A1NQO2PDE4BPDE4D | |
| SCHEMBL12053146 | 0.84 | CYP19A1 (0.41) | CYP19A1NQO2PDE4BPDE4D | |
| SCHEMBL730897 | 0.84 | NQO2 (0.46) | CYP19A1NQO2PDE4B | |
| SCHEMBL723600 | 0.83 | PDE4B (0.47) | CYP19A1NQO2PDE4B | |
| SCHEMBL730965 | 0.83 | CYP19A1 (0.45) | CYP19A1NQO2PDE4B | |
| SCHEMBL728717 | 0.82 | PDE4B (0.46) | CYP19A1NQO2PDE4B | |
| SCHEMBL726599 | 0.82 | PDE4B (0.46) | CYP19A1NQO2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078887-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078887-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078887-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2037924-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven P. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008006050-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006050-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP19A1 1277/4885NQO2 624/4885PDE4B 2/4885 |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP19A1 1573/4885NQO2 432/4885PDE4B 2/4885 |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP19A1 1277/4885NQO2 624/4885PDE4B 2/4885 |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP19A1 1277/4885NQO2 624/4885PDE4B 2/4885 |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP19A1 1277/4885NQO2 624/4885PDE4B 2/4885 |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP19A1 1277/4885NQO2 624/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.